Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.

Q2 Medicine Oncotarget Pub Date : 2017-05-24 eCollection Date: 2017-08-22 DOI:10.18632/oncotarget.18142

Xixi Zhao, Jingkun Qu, Yuxin Hui, Hong Zhang, Yuchen Sun, Xu Liu, Xiaoyao Zhao, Zitong Zhao, Qian Yang, Feidi Wang, Shuqun Zhang

{"title":"Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.","authors":"Xixi Zhao, Jingkun Qu, Yuxin Hui, Hong Zhang, Yuchen Sun, Xu Liu, Xiaoyao Zhao, Zitong Zhao, Qian Yang, Feidi Wang, Shuqun Zhang","doi":"10.18632/oncotarget.18142","DOIUrl":null,"url":null,"abstract":"Background: c-Met has been shown to promote organ development and cancer progression in many cancers. However, clinicopathological and prognostic value of c-Met in breast cancer remains elusive.Methods: PubMed and EMBASE databases were searched for eligible studies. Correlation of c-Met overexpression with survival data and clinicopathological features was analyzed by using hazard ratio (HR) or odds ratio (OR) and fixed-effect or random-effect model according to heterogeneity. All statistical tests were two-sided.Results: 32 studies with 8281 patients were analyzed in total. The c-Met overexpression was related to poor OS (overall survival) (HR=1.65 (1.328, 2.051)) of 18 studies with 4751 patients and poor RFS/DFS (relapse/disease free survival) (HR=1.53 (1.20, 1.95)) of 12 studies with 3598 patients. Subgroup analysis according to data source/methods/ethnicity showed c-Met overexpression was related to worse OS and RFS/DFS in Given by author group, all methods group and non-Asian group respectively. Besides, c-Met overexpression was associated with large tumor size, high histologic grade and metastasis.Conclusions: Our results showed that c-Met overexpression was connected with poor survival rates and malignant activities of cancer, including proliferation, migration and invasion, which highlighted the potential of c-Met as significant candidate biomarker to identify patients with breast cancer at high risk of tumor death.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":" ","pages":"56758-56767"},"PeriodicalIF":0.0000,"publicationDate":"2017-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593599/pdf/","citationCount":"23","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncotarget","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncotarget.18142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/8/22 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 23

Abstract

Background: c-Met has been shown to promote organ development and cancer progression in many cancers. However, clinicopathological and prognostic value of c-Met in breast cancer remains elusive.

Methods: PubMed and EMBASE databases were searched for eligible studies. Correlation of c-Met overexpression with survival data and clinicopathological features was analyzed by using hazard ratio (HR) or odds ratio (OR) and fixed-effect or random-effect model according to heterogeneity. All statistical tests were two-sided.

Results: 32 studies with 8281 patients were analyzed in total. The c-Met overexpression was related to poor OS (overall survival) (HR=1.65 (1.328, 2.051)) of 18 studies with 4751 patients and poor RFS/DFS (relapse/disease free survival) (HR=1.53 (1.20, 1.95)) of 12 studies with 3598 patients. Subgroup analysis according to data source/methods/ethnicity showed c-Met overexpression was related to worse OS and RFS/DFS in Given by author group, all methods group and non-Asian group respectively. Besides, c-Met overexpression was associated with large tumor size, high histologic grade and metastasis.

Conclusions: Our results showed that c-Met overexpression was connected with poor survival rates and malignant activities of cancer, including proliferation, migration and invasion, which highlighted the potential of c-Met as significant candidate biomarker to identify patients with breast cancer at high risk of tumor death.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺癌c-Met过表达的临床病理及预后意义

背景:c-Met已被证明在许多癌症中促进器官发育和癌症进展。然而，c-Met在乳腺癌中的临床病理和预后价值尚不明确。方法:检索PubMed和EMBASE数据库，寻找符合条件的研究。根据异质性，采用风险比(HR)或优势比(or)和固定效应或随机效应模型分析c-Met过表达与生存数据和临床病理特征的相关性。所有统计检验均为双侧检验。结果:共分析32项研究，8281例患者。c-Met过表达与18项研究中4751例患者较差的OS(总生存期)(HR=1.65(1.328, 2.051))和12项研究中3598例患者较差的RFS/DFS(复发/无病生存期)(HR=1.53(1.20, 1.95))相关。根据数据来源/方法/种族进行的亚组分析显示，作者组、所有方法组和非亚洲组的c-Met过表达分别与较差的OS和RFS/DFS有关。此外，c-Met过表达与肿瘤体积大、组织学分级高和转移有关。结论:我们的研究结果表明，c-Met过表达与癌症的低生存率和恶性活动(包括增殖、迁移和侵袭)有关，这突出了c-Met作为识别肿瘤死亡高风险乳腺癌患者的重要候选生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助